Charuwan Akewanlop

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +15

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Roy S. Herbst, Yi‐Long Wu, Thomas John et al. · Journal of Clinical Oncology · 2023 · 389 citations · Full text

Medicine, Oncology, Pharmacology +17

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Yi‐Long Wu, Thomas John, Christian Grohé et al. · Journal of Thoracic Oncology · 2021 · 151 citations · Full text

Medicine, Oncology, Pharmacology +14

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

Hope S. Rugo, Abhijit Barve, Cornelius F. Waller et al. · JAMA · 2016 · 145 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study

Lucksamon Thamlikitkul, Vichien Srimuninnimit, Charuwan Akewanlop et al. · Supportive Care in Cancer · 2016 · 63 citations

Medicine, Oncology, Pharmacology +17